Literature DB >> 15966501

The interaction of plasma renin activity and plasma atrial natriuretic peptide in 21-hydroxylase deficiency patients.

C M R Germano1, M de Castro, J C Crescencio, L Gallo, J Antunes-Rodrigues, A C Moreira, L L K Elias.   

Abstract

Plasma renin activity (PRA) determination is the main index used to evaluate the mineralocorticoid control in 21-hydroxylase deficiency (21-OHD). PRA values within or at the upper limit of the age-appropriate range, or values <5 or 10 ng/ml/h have been regarded as adequate control. Atrial natriuretic peptide (ANP) has opposite actions to those of angiotensin II/aldosterone, and could help to understand the hydrosaline homeostasis in 21-OHD. We studied the interaction between PRA and ANP levels in 10 controls and 26 patients with 21-OHD under corticoid treatment. Patients were divided into two groups according to PRA levels, < or > or = 5 ng/ml/h, irrespective of the clinical form of 21-OHD. Blood samples for determination of PRA and ANP levels were taken after 30 min in the sitting position (basal), after 30 min in the recumbent position and after 15 min of 20 degrees head-down tilting. ANP levels (pg/ml) in the basal, supine and after head-down tilting position were 25.9 +/- 1.6, 42.7 +/- 7.4 and 54.3 +/- 5.5 in controls; 28.5 +/- 2.1, 38.3 +/- 2.1 and 48.8 +/- 4.1 in the group with PRA levels <5 ng/ml/h, and 20.9 +/- 1.9, 26.6 +/- 2.5 and 34.6 +/- 3.1 in the group with PRA levels > or = 5 ng/ml/h, respectively. Basal and after head-down tilting ANP plasma levels were similar between the controls and the group with PRA levels <5 ng/ml/h. However, the group of patients with PRA levels > or = 5 ng/ml/h showed lower basal and stimulated ANP levels compared to the control group (p<0.05). The decreased plasma ANP levels in the basal condition and after head-down tilting indicate a chronic contraction of the extracellular volume in 21-OHD patients with increased PRA levels. Therefore, mineralocorticoid deficiency is counteracted by decreased ANP secretion in order to preserve fluid and electrolyte homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15966501     DOI: 10.1007/bf03347194

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Congenital adrenal hyperplasia.

Authors:  L S Levine
Journal:  Pediatr Rev       Date:  2000-05

Review 2.  Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves in control of renal function.

Authors:  G F DiBona
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

Review 3.  Oxytocin, vasopressin and atrial natriuretic peptide control body fluid homeostasis by action on their receptors in brain, cardiovascular system and kidney.

Authors:  Samuel M McCann; José Antunes-Rodrigues; Marek Jankowski; Jolanta Gutkowska
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

4.  Atrial natriuretic peptide and fludrocortisone therapy in congenital adrenal hyperplasia.

Authors:  O Arisaka; A Hosaka; M Arisaka; N Shimura; Y Nakayama; Y Yamashiro; K Yabuta
Journal:  Acta Paediatr       Date:  1992-03       Impact factor: 2.299

Review 5.  Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

6.  Value of direct measurement of active renin concentrations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  C Krüger; K Höper; R Weissörtel; J Hensen; H G Dörr
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

7.  Plasma catecholamines in patients with Addison's disease.

Authors:  S R Bornstein; M Breidert; M Ehrhart-Bornstein; B Kloos; W A Scherbaum
Journal:  Clin Endocrinol (Oxf)       Date:  1995-02       Impact factor: 3.478

8.  Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia?

Authors:  L A Lopes; J M Dubuis; M B Vallotton; P C Sizonenko
Journal:  J Pediatr Endocrinol Metab       Date:  1998 Nov-Dec       Impact factor: 1.634

Review 9.  Neuroendocrine control of body fluid metabolism.

Authors:  José Antunes-Rodrigues; Margaret de Castro; Lucila L K Elias; Marcelo M Valença; Samuel M McCann
Journal:  Physiol Rev       Date:  2004-01       Impact factor: 37.312

10.  Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans.

Authors:  C Peterson; B Madsen; A Perlman; A Y Chan; B D Myers
Journal:  Kidney Int       Date:  1988-12       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.